Brief: Bellicum presents clinical results to date of BPX-501 pediatric program
05/12/2016 21:15
Dec 5 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* Bellicum presents clinical results to date of BPX-501
pediatric program and provides regulatory update at investor
event during ash annual meeting
* Bellicum Pharmaceuticals - protocol assistance provided by
European Medicines Agency (EMA) for registration study of
BPX-501 in EUROPE is complete
* Finalizing plans for BP-004 trial extension
* Anticipates that it could pursue approval in EU under
"exceptional circumstances" provision
* Bellicum Pharmaceuticals - continues to discuss regulatory
path to approval in U.S. with FDA and expects to provide an
update in first half of 2017
Source text for Eikon: ID:nBw70TXVXa
Further company coverage: BLCM.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview